Merck Partners with Infinimmune in $838 Million Antibody Discovery Deal

Infinimmune has announced a strategic collaboration with pharmaceutical giant Merck to discover and develop multiple therapeutic antibodies. The agreement is potentially valued at up to $838 million, primarily structured through milestone-based payments tied to successful development and commercialization. Under the terms of the pact, the companies will leverage Infinimmune's proprietary discovery platform to target a range of undisclosed disease targets. This partnership underscores Merck's ongoing commitment to expanding its early-stage drug pipeline through innovative biotechnology collaborations. While the immediate financial impact on Merck's large-cap valuation is expected to be moderate, the deal provides significant validation for Infinimmune’s technological capabilities. Investors are closely monitoring the biotech sector as major pharmaceutical firms continue to seek external innovation to drive future growth.